Published in Mol Biosyst on February 08, 2012
Salivary biomarker development using genomic, proteomic and metabolomic approaches. Genome Med (2012) 1.16
Saliva as a diagnostic tool for oral and systemic diseases. J Oral Biol Craniofac Res (2015) 0.93
Advances of Proteomic Sciences in Dentistry. Int J Mol Sci (2016) 0.90
Salivary proteins associated with hyperglycemia in diabetes: a proteomic analysis. Mol Biosyst (2013) 0.88
Salivary biomarkers in a biofilm overgrowth model. J Periodontol (2014) 0.82
Development of isotope labeling LC-MS for human salivary metabolomics and application to profiling metabolome changes associated with mild cognitive impairment. Anal Chem (2012) 0.82
Elucidating role of salivary proteins in denture stomatitis using a proteomic approach. Mol Biosyst (2012) 0.78
Role of salivary and candidal proteins in denture stomatitis: an exploratory proteomic analysis. Mol Biosyst (2014) 0.78
Mass spectrometry as a tool for studying autism spectrum disorder. J Mol Psychiatry (2013) 0.77
α-2-macroglobulin in saliva is associated with glycemic control in patients with type 2 diabetes mellitus. Dis Markers (2015) 0.76
Minireview: progress and challenges in proteomics data management, sharing, and integration. Mol Endocrinol (2012) 0.76
Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases. Exp Biol Med (Maywood) (2016) 0.75
Salivary Diagnostics-Point-of-Care diagnostics of MMP-8 in dentistry and medicine. Diagnostics (Basel) (2017) 0.75
Salivary peptidome profiling analysis for occurrence of new carious lesions in patients with severe early childhood caries. PLoS One (2017) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2005) 4.55
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10
Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care (2005) 3.93
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 2.96
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: periodontitis and atherosclerotic cardiovascular disease. Am J Cardiol (2009) 2.91
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med (2002) 2.77
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2003) 2.46
1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care (2006) 2.44
Third molars associated with periodontal pathology in older Americans. J Oral Maxillofac Surg (2005) 2.40
Periodontal disease and coronary heart disease: a reappraisal of the exposure. Circulation (2005) 2.36
The American Journal of Cardiology and Journal of Periodontology editors' consensus: periodontitis and atherosclerotic cardiovascular disease. J Periodontol (2009) 2.20
Structural and evolutionary division of phosphotyrosine binding (PTB) domains. J Mol Biol (2005) 2.19
Systemic effects of periodontitis: epidemiology of periodontal disease and cardiovascular disease. J Periodontol (2005) 2.19
Fetal exposure to oral pathogens and subsequent risk for neonatal intensive care admission. J Periodontol (2009) 2.17
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2015) 2.13
Maternal periodontal disease is associated with an increased risk for preeclampsia. Obstet Gynecol (2003) 2.12
Relationship between periodontal disease and C-reactive protein among adults in the Atherosclerosis Risk in Communities study. Arch Intern Med (2003) 2.06
Periodontal disease and cardiovascular disease: epidemiology and possible mechanisms. J Am Dent Assoc (2002) 1.95
Associations between IgG antibody to oral organisms and carotid intima-medial thickness in community-dwelling adults. Atherosclerosis (2005) 1.94
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91
Proteomic identification of the cerebral cavernous malformation signaling complex. J Proteome Res (2007) 1.83
Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. Am J Geriatr Psychiatry (2011) 1.83
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care (2013) 1.79
Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet (2006) 1.74
Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kidney Int (2009) 1.74
Greater risk of dementia when spouse has dementia? The Cache County study. J Am Geriatr Soc (2010) 1.73
Prevention or delay of type 2 diabetes. Diabetes Care (2004) 1.73
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol (2010) 1.68
Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry (2015) 1.65
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J (2013) 1.62
The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab (2011) 1.60
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
The Periodontitis and Vascular Events (PAVE) pilot study: adverse events. J Periodontol (2008) 1.55
The relationship between self-reported history of endodontic therapy and coronary heart disease in the Atherosclerosis Risk in Communities Study. J Am Dent Assoc (2009) 1.54
Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals. Environ Health Perspect (2008) 1.53
Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. J Biol Chem (2010) 1.51
Periodontal disease early in pregnancy is associated with maternal systemic inflammation among African American women. J Periodontol (2008) 1.50
Oral reconstructive and corrective considerations in periodontal therapy. J Periodontol (2005) 1.49
Exploring the relationship between periodontal disease and pregnancy complications. J Am Dent Assoc (2006) 1.47
Periodontal regeneration. J Periodontol (2005) 1.47
Relationships among clinical measures of periodontal disease and their associations with systemic markers. Ann Periodontol (2002) 1.46
The oral conditions and pregnancy study: periodontal status of a cohort of pregnant women. J Periodontol (2004) 1.46
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2007) 1.44
Potential for gingival crevice fluid measures as predictors of risk for periodontal diseases. Periodontol 2000 (2003) 1.42
Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. J Mol Biol (2005) 1.40
Maternal periodontal disease in early pregnancy and risk for a small-for-gestational-age infant. Am J Obstet Gynecol (2006) 1.31
Electronic communications and home blood pressure monitoring (e-BP) study: design, delivery, and evaluation framework. Contemp Clin Trials (2007) 1.31
Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease. Periodontol 2000 (2006) 1.29
Porphyromonas gingivalis bacteremia induces coronary and aortic atherosclerosis in normocholesterolemic and hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol (2005) 1.26
The effects of periodontal therapy on vascular endothelial function: a pilot trial. Am Heart J (2006) 1.26
Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol (2007) 1.25
Exploring the genetic basis of chronic periodontitis: a genome-wide association study. Hum Mol Genet (2013) 1.23
Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways. Proc Natl Acad Sci U S A (2013) 1.20
Trophoblast stem cell maintenance by fibroblast growth factor 4 requires MEKK4 activation of Jun N-terminal kinase. Mol Cell Biol (2009) 1.19
Periodontal pathology associated with asymptomatic third molars. J Oral Maxillofac Surg (2002) 1.18
Periodontitis and diabetes associations with measures of atherosclerosis and CHD. Atherosclerosis (2012) 1.18
Maternal periodontal disease, systemic inflammation, and risk for preeclampsia. Am J Obstet Gynecol (2008) 1.17
A perspective on the potential cardioprotective benefits of periodontal therapy. Am Heart J (2005) 1.16
Porphyromonas gingivalis infection in pregnant mice is associated with placental dissemination, an increase in the placental Th1/Th2 cytokine ratio, and fetal growth restriction. Infect Immun (2003) 1.15
Postdischarge pharmacist medication reconciliation: impact on readmission rates and financial savings. J Am Pharm Assoc (2003) (2013) 1.13
Clinical risk factors associated with incidence and progression of periodontal conditions in pregnant women. J Clin Periodontol (2005) 1.11
Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care (2012) 1.11
Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J (2008) 1.11
Progression of periodontal disease in the second/third molar region in subjects with asymptomatic third molars. J Oral Maxillofac Surg (2006) 1.10
Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol (2002) 1.10
Vitamin D status and periodontal disease among pregnant women. J Periodontol (2010) 1.08
Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals. Part Fibre Toxicol (2010) 1.07
Persistently high levels of periodontal pathogens associated with preterm pregnancy outcome. J Periodontol (2007) 1.07
Relationship of periodontal disease and tooth loss to prevalence of coronary heart disease. J Periodontol (2004) 1.06
Third molars associated with periodontal pathology in the Third National Health and Nutrition Examination Survey. J Oral Maxillofac Surg (2004) 1.06
Antibodies to periodontal organisms are associated with decreased kidney function. The Dental Atherosclerosis Risk In Communities study. Blood Purif (2006) 1.06
IL1B gene promoter haplotype pairs predict clinical levels of interleukin-1beta and C-reactive protein. Hum Genet (2008) 1.06
Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care (2011) 1.04
Maternal serum C-reactive protein concentration early in pregnancy and subsequent pregnancy loss. Am J Perinatol (2005) 1.03
Optimal timing of periodontal disease treatment for prevention of adverse pregnancy outcomes: before or during pregnancy? Am J Obstet Gynecol (2011) 1.03
Porphyromonas gingivalis infection during pregnancy increases maternal tumor necrosis factor alpha, suppresses maternal interleukin-10, and enhances fetal growth restriction and resorption in mice. Infect Immun (2003) 1.03
Relationship of hearing loss and dementia: a prospective, population-based study. Otol Neurotol (2014) 1.03
Effect of non-surgical periodontal therapy on C-reactive protein, oxidative stress, and matrix metalloproteinase (MMP)-9 and MMP-2 levels in patients with type 2 diabetes: a randomized controlled study. J Periodontol (2011) 1.01
Racial differences in C-reactive protein levels during normal pregnancy. Am J Obstet Gynecol (2008) 1.01
Aortic arch atheroma progression and recurrent vascular events in patients with stroke or transient ischemic attack. Circulation (2007) 1.01
Chronic maternal and fetal Porphyromonas gingivalis exposure during pregnancy in rabbits. Am J Obstet Gynecol (2005) 1.00